7 months ago
JNJ
AnalystsAsad HaiderAsad Haider's Stock Forecasts
AnalystsAsad Haider
Sectors:
Industries:
Analyst Ranking
Top 46%
#2300 out of 5087 analysts
Average Return
+9.89%
Win Rate
80%4 out of 5
Risk vs Reward
Poor
Good
Asad Haider's 5 best and worst ratings
| Name / Ticker | Gain/Loss | Entry Price | Exit Price | Period | Rating |
|---|---|---|---|---|---|
Johnson & JohnsonJNJ | +25.10% | $150.97 | $188.87 | 2025-04-09 - 2025-10-31 | Strong Buy |
Eli Lilly & CoLLY | +18.81% | $726.24 | $862.86 | 2025-04-08 - 2025-10-31 | Strong Buy |
Royalty Pharma PLCRPRX | +6.41% | $35.28 | $37.54 | 2025-09-30 - 2025-10-31 | Strong Buy |
Innoviva IncINVA | +0.27% | $18.25 | $18.20 | 2025-09-30 - 2025-10-31 | Strong Sell |
Asad Haider Analyst Color
Get additional color on Asad Haider's coverage of popular stocks
7 months ago
LLY
7 months ago
PFE
Asad Haider's Stock Coverage
| Name / Ticker | No. Ratings | Rating | Price Target | Upside/Downside | Action | Date |
|---|---|---|---|---|---|---|
Johnson & JohnsonJNJ | 2 | Strong Buy | $212.00 | +12.25% | Maintains | 25 days ago |
Innoviva IncINVA | 1 | Strong Sell | $17.00 | -6.59% | Initiates Coverage On | a month ago |
Royalty Pharma PLCRPRX | 1 | Strong Buy | $42.00 | +11.88% | Initiates Coverage On | a month ago |
Vaxcyte IncPCVX | 1 | Hold | $38.00 | -16.08% | Initiates Coverage On | 2 months ago |
Newamsterdam Pharma Co NvNAMS | 1 | Hold | $27.00 | -28.85% | Initiates Coverage On | 4 months ago |
Biontech SeBNTX | 1 | Hold | $110.00 | +5.86% | Initiates Coverage On | 5 months ago |
Eli Lilly & CoLLY | 1 | Strong Buy | $888.00 | +2.91% | Upgrades | 7 months ago |
Abbvie IncABBV | 1 | Hold | $194.00 | -11.03% | Assumes | 7 months ago |
Pfizer IncPFE | 1 | Hold | $25.00 | +1.42% | Downgrades | 7 months ago |
Bristol Myers Squibb CoBMY | 1 | Hold | $55.00 | +19.38% | Downgrades | 7 months ago |
Company
AboutNewsBlogStock Investing FAQPlansPrivacy PolicyTerms of ServiceCancellation & RefundsPerformanceHelp GuidesContactTwitterYouTubeNewsletterWallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.